Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity

Trial Profile

Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 18 Sep 2017.
    • 01 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top